Deus Simon Ishengoma

Deus Simon Ishengoma

Auto-generated profile, based on publicly available information

Deus Simon Ishengoma

Ifakara Health Institute, Dar es Salaam, Tanzania

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
EKEdwin Kamau
Edwin Kamau
SCSusana Campino
Susana Campino
Lucas Amenga-EtegoLucas Amenga-Etego
Lucas Amenga-Etego
EDEleanor Drury
Eleanor Drury
DIDeus Ishengoma
Deus Ishengoma
ADAbdoulaye A. Djimde
Abdoulaye A. Djimde
Mutations in the Plasmodium falciparum K13-propeller domain have recently been shown to be important determinants of artemisinin resistance in Southeast Asia. This study investigated the prevalence of K13-propeller polymorphisms across sub-Saharan Africa. A total of 1212 P. falciparum samples collected from 12 countries were sequenced. None of the K13-propeller mutations previously reported in Southeast Asia were found, but 22 unique mutations were detected, of which 7 were nonsynonymous. Allele frequencies ranged between 1% and 3%. Three mutations were observed in >1 country, and the A578S was present in parasites from 5 countries. This study provides the baseline prevalence of K13-propeller mutations in sub-Saharan Africa.

16 January 2023 in Wellcome Open Research
Verified
Journal Article
Open access
MNMalaria G E N
Malaria G E N
MHMuzamil Mahdi Abdel Hamid
Muzamil Mahdi Abdel Hamid
MAMohamed Hassan Abdelraheem
Mohamed Hassan Abdelraheem
DADesmond Omane Acheampong
Desmond Omane Acheampong
AAAmbroise Ahouidi
Ambroise Ahouidi
RPRob W van der Pluijm
Rob W van der Pluijm
We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS,S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short indels, analysis of large deletions that cause failure of rapid diagnostic tests, and systematic characterisation of six major drug resistance loci, all of which can be freely downloaded from the MalariaGEN website.

24 February 2021 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
MNMalaria G E N
Malaria G E N
AAAmbroise Ahouidi
Ambroise Ahouidi
MAMozam Ali
Mozam Ali
JAJacob Almagro-Garcia
Jacob Almagro-Garcia
AAAlfred Amambua-Ngwa
Alfred Amambua-Ngwa
HYHtut Ye
Htut Ye
MalariaGEN is a data-sharing network that enables groups around the world to work together on the genomic epidemiology of malaria. Here we describe a new release of curated genome variation data on 7,000 Plasmodium falciparum samples from MalariaGEN partner studies in 28 malaria-endemic countries. High-quality genotype calls on 3 million single nucleotide polymorphisms (SNPs) and short indels were produced using a standardised analysis pipeline. Copy number variants associated with drug resistance and structural variants that cause failure of rapid diagnostic tests were also analysed. Almost all samples showed genetic evidence of resistance to at least one antimalarial drug, and some samples from Southeast Asia carried markers of resistance to six commonly-used drugs. Genes expressed during the mosquito stage of the parasite life-cycle are prominent among loci that show strong geographic differentiation. By continuing to enlarge this open data resource we aim to facilitate research into the evolutionary processes affecting malaria control and to accelerate development of the surveillance toolkit required for malaria elimination.

10 December 2008 in Nature
Verified
Journal Article
Closed access
TNThe Malaria Genomic Epidemiology Network
The Malaria Genomic Epidemiology Network
LILead Investigators
Lead Investigators
EAEric Akum Achidi
Eric Akum Achidi
TATsiri Agbenyega
Tsiri Agbenyega
Stephen J. AllenStephen J. Allen
Stephen J. Allen
MGMichael Gottlieb
Michael Gottlieb

16 August 2024 in The Lancet Infectious Diseases
Verified
Journal Article
Open access
DIDeus S Ishengoma
Deus S Ishengoma
CMCeline I Mandara
Celine I Mandara
CBCatherine Bakari
Catherine Bakari
AFAbebe A Fola
Abebe A Fola
RMRashid A Madebe
Rashid A Madebe
MWMarian Warsame
Marian Warsame
In 2021, nationwide malaria molecular surveillance revealed a high prevalence of a validated artemisinin resistance marker, the kelch13 (k13) Arg561His mutation, in the Kagera region of northwestern Tanzania. We aimed to investigate the efficacy of artemether-lumefantrine and artesunate-amodiaquine and to confirm the presence of artemisinin partial resistance (ART-R) in the Karagwe district of this region. This single-arm, therapeutic efficacy study was carried out at the Bukangara dispensary in the Karagwe district of the Kagera region in northwestern Tanzania. Eligible participants were aged between 6 months and 120 months, had confirmed Plasmodium falciparum asexual parasitaemia, and met other inclusion criteria according to WHO's standard protocol. Participants were enrolled, treated sequentially with either artemether-lumefantrine or artesunate-amodiaquine, and assessed clinically and parasitologically for 28 days as per WHO protocol. Parasitaemia was measured every 8 h until day 3, on day 7, and then during weekly follow-up visits until day 28. Mutations in the k13 gene and extended haplotypes with the mutations were analysed, and comparisons were made with previous samples collected in the same region of Kagera and in Rwanda and southeast Asia. The primary endpoint was PCR-corrected cure rate. Between April 29 and Sept 1, 2022, 343 patients were screened, of whom 176 were enrolled: 88 in each treatment group. The PCR-corrected cure rate was 98% (95% CI 91-100) in the artemether-lumefantrine group and 100% (96-100) in the artesunate-amodiaquine group. Persistent parasitaemia on day 3 occurred in 11 (13%) of 88 patients in the artemether-lumefantrine group and 17 (19%) of 88 patients in the artesunate-amodiaquine group. Arg561His mutations on day 0 and parasitaemia on day 3 were reported in eight (9%) of 87 patients in the artemether-lumefantrine group and ten (12%) of 86 patients in the artesunate-amodiaquine group. The median parasite clearance half-life in patients harbouring parasites with Arg561His mutation was 6·1 h in the artemether-lumefantrine group and 6·0 h in the artesunate-amodiaquine group. Parasites with the Arg561His mutation were not similar to those from southeast Asia and Rwanda but had similar haplotypes to parasites reported in the same Tanzanian region of Kagera in 2021. This study confirms the presence of ART-R in Tanzania, although artemether-lumefantrine and artesunate-amodiaquine showed high efficacy. A context-specific response strategy and vigilance to detect the reduced efficacy of current antimalarial treatments and ART-R in other parts of the country are urgently needed. The Bill & Melinda Gates Foundation and the US National Institutes of Health.

1 August 2021 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
LNLeonard Ndwiga
Leonard Ndwiga
KKKelvin M. Kimenyi
Kelvin M. Kimenyi
KWKevin Wamae
Kevin Wamae
VOVictor Osoti
Victor Osoti
MAMercy Akinyi
Mercy Akinyi
LOLynette Isabella Ochola-Oyier
Lynette Isabella Ochola-Oyier
Artemisinin resistance (AR) emerged in South East Asia 13 years ago and the identification of the resistance conferring molecular marker, Plasmodium falciparum Kelch 13 (Pfk13), 7 years ago has provided an invaluable tool for monitoring AR in malaria endemic countries. Molecular Pfk13 surveillance revealed the resistance foci in the Greater Mekong Subregion, an independent emergence in Guyana, South America, and a low frequency of mutations in Africa. The recent identification of the R561H Pfk13 AR associated mutation in Tanzania, Uganda and in Rwanda, where it has been associated with delayed parasite clearance, should be a concern for the continent. In this review, we provide a summary of Pfk13 resistance associated propeller domain mutation frequencies across Africa from 2012 to 2020, to examine how many other countries have identified these mutations. Only four African countries reported a recent identification of the M476I, P553L, R561H, P574L, C580Y and A675V Pfk13 mutations at low frequencies and with no reports of clinical treatment failure, except for Rwanda. These mutations present a threat to malaria control across the continent, since the greatest burden of malaria remains in Africa. A rise in the frequency of these mutations and their spread would reverse the gains made in the reduction of malaria over the last 20 years, given the lack of new antimalarial treatments in the event artemisinin-based combination therapies fail. The review highlights the frequency of Pfk13 propeller domain mutations across Africa, providing an up-to-date perspective of Pfk13 mutations, and appeals for an urgent and concerted effort to monitoring antimalarial resistance markers in Africa and the efficacy of antimalarials by re-establishing sentinel surveillance systems.